Liminatus Pharma, Inc. (NASDAQ:LIMN) Financings

Liminatus Pharma, Inc.

Financings

RaiseDate
Public offering of common stock (or pre-funded warrants) and accompanying warrants
Announced: about US$4M · US$0.29 a share · Warrants at US$0.29 for 60 months · Maxim Group LLC
Dealers: Maxim Group LLC (lead)
Use of proceeds: Working capital, general corporate purposes and advancing the company's business objectives
Feb 17, 2026
Strategic investment of newly issued shares
Announced: US$30M
Buyers: Capital Trust Group Limited (USD 30,000,000 equity financing via subscription for newly issued shares)
Use of proceeds: Research and development of advanced immunotherapy assets
Oct 30, 2025
Not stated
Announced: up to US$500M · Digital Offering
Dealers: Digital Offering (lead)
Use of proceeds: Acquisition and long-term holding of BNB Coin through the planned American BNB Strategy subsidiary
Jul 28, 2025

Read by 6ix AI from the company's releases